Roche has axed one-fifth of its pipeline since the third quarter of 2023 as part of a broader portfolio review aimed at ...

Biogen recorded higher-than-expected revenue for the lead rare disease drug from its $7 billion acquisition of Reata ...

Flindr Therapeutics has secured €20 million ($21 million) in a Series A raise aimed at advancing its lead program through an ...

Novartis’ Lutathera is now the first radiopharmaceutical approved for adolescents with a rare cancer found in the gut. The ...

The FDA granted accelerated approval to Day One Biopharmaceuticals' pediatric brain tumor treatment. The regulator on Tuesday ...

China’s GNI Group announced on April 18 that it has signed an agreement with Chinese state-owned enterprises and ...

Stephanie DeViteri is taking over as Inizio Evoke Comms’ president for North America, returning to the agency where she spent ...

Tessera Therapeutics, Flagship’s major bet on what it calls gene writing, is letting go 13% to 14% of its workforce, a ...

Pfizer and Novo Nordisk are both set to take the main stages at Cannes' advertising confab this summer. The just-announced ...

In the 37 years since co-founding ARCH Venture Partners, Bob Nelsen has built a reputation for placing head-turning bets on ...

Novartis appears headed in the right direction now that Sandoz has been spun out, operations have been streamlined and the ...

Endpoints News reported that former Stanford president Marc Tessier-Lavigne will lead one of biotech’s biggest-ever startup ...